help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on December 7, 2004
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-0545
A more recent version of this article appeared on March 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
90/3/1864    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gola, M.
Right arrow Articles by Giustina, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gola, M.
Right arrow Articles by Giustina, A.

Submitted on March 21, 2004
Accepted on November 29, 2004

Growth hormone (GH) and cardiovascular risk factors

Monica Gola, Stefania Bonadonna, Mauro Doga, and Andrea Giustina*

Endocrine Section, Dept. of Internal Medicine, University of Brescia, Italy

* To whom correspondence should be addressed. E-mail: a.giustina{at}libero.it.

Aim the this perspective article will be to briefly review the lessons we learnt from the study of GHD on the relationship between GH and the principal metabolic cardiovascular risk factors and to critically evaluate to partial involvement of "subclinical" or perhaps better "functional" GHD in the increase in cardiovascular risk which is observed in aging and obesity. The lesson that "organic" GHD has taught to us is that primary impairment in the GH/IGF-1 axis may lead to a high risk cardiovascular profile which is partially reversible during GH replacement. We think that there are interesting analogies between the cardiovascular risk profile of situation of "functional" GHD such as aging and obesity with those of "organic" GHD. It remains to be demonstrated that intervention with GH can ameliorate this risk profile in functional as it happens in organic GHD. Lacking of this demonstration may not necessarily imply that "functional" GHD is rather a consequence than a cause of this risk profile but may also be linked to dose finding or to dimension of the study sample as well as length of follow-up.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
G. Li, J.-P. del Rincon, L. A. Jahn, Y. Wu, B. Gaylinn, M. O. Thorner, and Z. Liu
Growth Hormone Exerts Acute Vascular Effects Independent of Systemic or Muscle Insulin-like Growth Factor I
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1379 - 1385.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. M. Martin, D. Gunnell, E. Whitley, A. Nicolaides, M. Griffin, N. Georgiou, G. Davey Smith, S. Ebrahim, and J. M. P. Holly
Associations of Insulin-Like Growth Factor (IGF)-I, IGF-II, IGF Binding Protein (IGFBP)-2 and IGFBP-3 with Ultrasound Measures of Atherosclerosis and Plaque Stability in an Older Adult Population
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1331 - 1338.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
H. Jorn Schneider, J. Klotsche, B. Saller, S. Bohler, C. Sievers, D. Pittrow, G. Ruf, W. Marz, W. Erwa, A. M Zeiher, et al.
Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients
Eur. J. Endocrinol., February 1, 2008; 158(2): 153 - 161.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. L. M. Oliveira, M. H. Aguiar-Oliveira, A. D'Oliveira Jr, R. M. C. Pereira, C. R. P. Oliveira, C. T. Farias, J. A. Barreto-Filho, F. D. Anjos-Andrade, C. Marques-Santos, A. C. Nascimento-Junior, et al.
Congenital Growth Hormone (GH) Deficiency and Atherosclerosis: Effects of GH Replacement in GH-Naive Adults
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4664 - 4670.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
H. J. Schneider, I. Kreitschmann-Andermahr, E. Ghigo, G. K. Stalla, and A. Agha
Hypothalamopituitary Dysfunction Following Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage: A Systematic Review
JAMA, September 26, 2007; 298(12): 1429 - 1438.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Maison, A.-I. Tropeano, I. Macquin-Mavier, A. Giustina, and P. Chanson
Impact of Somatostatin Analogs on the Heart in Acromegaly: A Metaanalysis
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1743 - 1747.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Rizzo, R. Trepp, K. Berneis, and E. R Christ
Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy
Eur. J. Endocrinol., March 1, 2007; 156(3): 361 - 367.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Bondanelli, M. R. Ambrosio, A. Onofri, A. Bergonzoni, S. Lavezzi, M. C. Zatelli, D. Valle, N. Basaglia, and E. C. degli Uberti
Predictive Value of Circulating Insulin-Like Growth Factor I Levels in Ischemic Stroke Outcome
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3928 - 3934.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. L. Menezes Oliveira, C. Marques-Santos, J. A. Barreto-Filho, R. Ximenes Filho, A. V. de Oliveira Britto, A. H. Oliveira Souza, C. M. Prado, C. R. Pereira Oliveira, R. M. C. Pereira, T. de Almeida Ribeiro Vicente, et al.
Lack of Evidence of Premature Atherosclerosis in Untreated Severe Isolated Growth Hormone (GH) Deficiency due to a GH-Releasing Hormone Receptor Mutation
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2093 - 2099.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
J. Bollerslev, T. Ueland, A. P Jorgensen, K. J Fougner, R. Wergeland, T. Schreiner, and P. Burman
Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency.
Eur. J. Endocrinol., April 1, 2006; 154(4): 537 - 543.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Colao, C. Di Somma, A. Cuocolo, L. Spinelli, W. Acampa, S. Spiezia, F. Rota, M. C. Savanelli, and G. Lombardi
Does a Gender-Related Effect of Growth Hormone (GH) Replacement Exist on Cardiovascular Risk Factors, Cardiac Morphology, and Performance and Atherosclerosis? Results of a Two-Year Open, Prospective Study in Young Adult Men and Women with Severe GH Deficiency
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5146 - 5155.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society